Histone deacetylase inhibitors in lymphoma and solid malignancies (Q37118947)

18 August 2017

1 reference

title

Histone deacetylase inhibitors in lymphoma and solid malignancies (English)

1 reference

18 August 2017

Mark Bishton

2

0 references

Ricky W Johnstone

object named as

Ricky W Johnstone

series ordinal

3

0 references

author name string

Walid Rasheed

series ordinal

1

1 reference

PubMed ID

18366289

18 August 2017

H Miles Prince

series ordinal

4

1 reference

18 August 2017

1 March 2008

1 reference

Expert Review of Anticancer Therapy

18 August 2017

1 reference

18 August 2017

8

1 reference

18 August 2017

413-432

1 reference

18 August 2017

3

1 reference

Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer

18 August 2017

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.3.413

Histone deacetylase inhibitors: overview and perspectives

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.3.413

Histone deacetylase inhibitors: molecular mechanisms of action

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.3.413

Molecular evolution of the histone deacetylase family: functional implications of phylogenetic analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.3.413

Epigenetic and chromatin modifiers as targeted therapy of hematologic malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.3.413

Anticancer activities of histone deacetylase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.3.413

Epigenetic gene silencing in cancer – a mechanism for early oncogenic pathway addiction?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.3.413

Histone methylation versus histone acetylation: new insights into epigenetic regulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.3.413

Chromatin modification, leukaemia and implications for therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.3.413

Histone acetylation and disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.3.413

Histone deacetylases, transcriptional control, and cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.3.413

Histone deacetylase inhibitors in cancer treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.3.413

Histone deacetylase inhibitors: molecular and biological activity as a premise to clinical application.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.3.413

Role of histone deacetylases in acute leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.3.413

ETO, fusion partner in t(8;21) acute myeloid leukemia, represses transcription by interaction with the human N-CoR/mSin3/HDAC1 complex

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.3.413

Transcriptional regulation in acute promyelocytic leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.3.413

Development of histone deacetylase inhibitors for cancer treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.3.413

Loss of acetylation at Lys16 and trimethylation at Lys20 of histone H4 is a common hallmark of human cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.3.413

Sirtuins as potential targets for metabolic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.3.413

Prospects: histone deacetylase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.3.413

Rapid induction of histone hyperacetylation and cellular differentiation in human breast tumor cell lines following degradation of histone deacetylase-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.3.413

Epigenetic targets in hematological malignancies: combination therapies with HDACis and demethylating agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.3.413

Induction of apoptosis in U937 human leukemia cells by suberoylanilide hydroxamic acid (SAHA) proceeds through pathways that are regulated by Bcl-2/Bcl-XL, c-Jun, and p21CIP1, but independent of p53

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.3.413

Histone deacetylase inhibitor selectively induces p21WAF1 expression and gene-associated histone acetylation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.3.413

Histone modifying enzymes and cancer: going beyond histones.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.3.413

Worms gang up on bacteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.3.413

Diallyl disulfide (DADS) increases histone acetylation and p21(waf1/cip1) expression in human colon tumor cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.3.413

A novel mechanism of chemoprotection by sulforaphane: inhibition of histone deacetylase.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.3.413

Induction of HDAC2 expression upon loss of APC in colorectal tumorigenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.3.413

The histone deacetylase inhibitor SAHA arrests cancer cell growth, up-regulates thioredoxin-binding protein-2, and down-regulates thioredoxin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.3.413

The histone deacetylase inhibitor and chemotherapeutic agent suberoylanilide hydroxamic acid (SAHA) induces a cell-death pathway characterized by cleavage of Bid and production of reactive oxygen species

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.3.413

Analysis of the apoptotic and therapeutic activities of histone deacetylase inhibitors by using a mouse model of B cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.3.413

Selective induction of apoptosis by histone deacetylase inhibitor SAHA in cutaneous T-cell lymphoma cells: relevance to mechanism of therapeutic action

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.3.413

Clinical experience with intravenous and oral formulations of the novel histone deacetylase inhibitor suberoylanilide hydroxamic acid in patients with advanced hematologic malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.3.413

Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL)

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.3.413

Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.3.413

Dimethyl sulfoxide to vorinostat: development of this histone deacetylase inhibitor as an anticancer drug

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.3.413

Vorinostat for treatment of cutaneous manifestations of advanced primary cutaneous T-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.3.413

T-cell lymphoma as a model for the use of histone deacetylase inhibitors in cancer therapy: impact of depsipeptide on molecular markers, therapeutic targets, and mechanisms of resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.3.413

Inhibitor of histone deacetylation, depsipeptide (FR901228), in the treatment of peripheral and cutaneous T-cell lymphoma: a case report

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.3.413

Quantitative PCR on 5 genes reliably identifies CTCL patients with 5% to 99% circulating tumor cells with 90% accuracy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.3.413

Phase I and pharmacokinetic study of MS-275, a histone deacetylase inhibitor, in patients with advanced and refractory solid tumors or lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.3.413

Histone deacetylase inhibitors down-regulate bcl-2 expression and induce apoptosis in t(14;18) lymphomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.3.413

Suberoylanilide hydroxamic acid (SAHA; vorinostat) suppresses translation of cyclin D1 in mantle cell lymphoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.3.413

Histone deacetylase inhibitors reduce VEGF production and induce growth suppression and apoptosis in human mantle cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.3.413

Selective efficacy of depsipeptide in a xenograft model of Epstein-Barr virus-positive lymphoproliferative disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.3.413

Histone deacetylase inhibitors induce growth arrest and apoptosis of HTLV-1-infected T-cells via blockade of signaling by nuclear factor kappaB.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.3.413

Combined effects of histone deacetylase inhibitor and rituximab on non-Hodgkin's B-lymphoma cells apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.3.413

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.3.413

Histone deacetylase inhibitors potentiate TNF-related apoptosis-inducing ligand (TRAIL)-induced apoptosis in lymphoid malignancies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.3.413

Activity of pivaloyloxymethyl butyrate, a novel anticancer agent, on primary human tumor colony-forming units.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.3.413

The selectivty and anti-metastatic activity of oral bioavailable butyric acid prodrugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.3.413

Bombesin/gastrin-releasing peptide receptor antagonists increase the ability of histone deacetylase inhibitors to reduce lung cancer proliferation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.3.413

Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.3.413

Potential role of histone deacetylase inhibitors in mesothelioma: clinical experience with suberoylanilide hydroxamic acid.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.3.413

Phase II trial of the histone deacetylase inhibitor pivaloyloxymethyl butyrate (Pivanex, AN-9) in advanced non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.3.413

Antitumor activity of suberoylanilide hydroxamic acid against thyroid cancer cell lines in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.3.413

Valproic acid induces apoptosis and cell cycle arrest in poorly differentiated thyroid cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.3.413

Histone deacetylase inhibitors promote apoptosis and differential cell cycle arrest in anaplastic thyroid cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.3.413

Multiple Molecular pathways explain the anti-proliferative effect of valproic acid on prostate cancer cells in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.3.413

Epigenetic modulation of retinoic acid receptor beta2 by the histone deacetylase inhibitor MS-275 in human renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.3.413

Suberoylanilide hydroxamic acid combined with gemcitabine enhances apoptosis in non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.3.413

Phase I and pharmacokinetic study of vorinostat, a histone deacetylase inhibitor, in combination with carboplatin and paclitaxel for advanced solid malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.3.413

Gemcitabine plus CI-994 offers no advantage over gemcitabine alone in the treatment of patients with advanced pancreatic cancer: results of a phase II randomized, double-blind, placebo-controlled, multicenter study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.3.413

Sequence-dependent antitumor effects of differentiation agents in combination with cell cycle-dependent cytotoxic drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.3.413

Suberoylanilide hydroxamic acid (vorinostat) represses androgen receptor expression and acts synergistically with an androgen receptor antagonist to inhibit prostate cancer cell proliferation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.3.413

Valproic acid, a histone deacetylase inhibitor, enhances sensitivity to doxorubicin in anaplastic thyroid cancer cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.3.413

Valproic acid enhances tubulin acetylation and apoptotic activity of paclitaxel on anaplastic thyroid cancer cell lines.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.3.413

A histone deacetylase inhibitor enhances killing of undifferentiated thyroid carcinoma cells by p53 gene therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.3.413

Histone deacetylase inhibitors and demethylating agents: clinical development of histone deacetylase inhibitors for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.3.413

A phase I trial of depsipeptide (FR901228) in patients with advanced cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.3.413

Targeted induction of apoptosis in cancer management: the emerging role of tumor necrosis factor-related apoptosis-inducing ligand receptor activating agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.3.413

Molecularly targeted oncology therapeutics and prolongation of the QT interval

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.3.413

Oral sodium phenylbutyrate in patients with recurrent malignant gliomas: a dose escalation and pharmacologic study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.3.413

A study of a different dose-intense infusion schedule of phenylacetate in patients with recurrent primary brain tumors consortium report.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.3.413

Chronic oral administration of CI-994: a phase 1 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.3.413

Phase I study of oral CI-994 in combination with gemcitabine in treatment of patients with advanced cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.3.413

A phase I study of the oral combination of CI-994, a putative histone deacetylase inhibitor, and capecitabine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.3.413

Phase I study of oral CI-994 in combination with carboplatin and paclitaxel in the treatment of patients with advanced solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.3.413

Phase I trial and pharmacokinetics of gemcitabine in children with advanced solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.3.413

Molecular pathogenesis of non-Hodgkin's lymphoma: the role of Bcl-6

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.3.413

Histone deacetylase inhibitors in cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.3.413

21 January 2018

Identifiers

DOI

10.1586/14737140.8.3.413

1 reference

18 August 2017

1 reference

PubMed ID

18366289